Research Analysts’ Recent Ratings Updates for Nuvation Bio (NUVB)

Nuvation Bio (NYSE: NUVB) has recently received a number of price target changes and ratings updates:

• 12/11/2025 – Nuvation Bio had its price target raised by analysts at HC Wainwright from $10.00 to $18.00. They now have a “buy” rating on the stock.
• 12/1/2025 – Nuvation Bio had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
• 11/24/2025 – Nuvation Bio was given a new $11.00 price target on by analysts at Truist Financial Corporation.
• 11/24/2025 – Nuvation Bio is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $11.00 price target on the stock.
• 11/20/2025 – Nuvation Bio was given a new $10.00 price target on by analysts at JMP Securities.
• 11/20/2025 – Nuvation Bio had its price target raised by analysts at Citizens Jmp from $8.00 to $10.00. They now have a “market outperform” rating on the stock.
• 11/19/2025 – Nuvation Bio is now covered by analysts at B. Riley. They set a “buy” rating and a $12.00 price target on the stock.
• 11/18/2025 – Nuvation Bio is now covered by analysts at B. Riley. They set a “buy” rating and a $12.00 price target on the stock.
• 11/4/2025 – Nuvation Bio was given a new $8.00 price target on by analysts at JMP Securities.
• 11/4/2025 – Nuvation Bio had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..
• 11/4/2025 – Nuvation Bio had its price target raised by analysts at Royal Bank Of Canada from $7.00 to $8.00. They now have an “outperform” rating on the stock.
• 11/4/2025 – Nuvation Bio had its price target raised by analysts at Citizens Jmp from $6.00 to $8.00. They now have a “market outperform” rating on the stock.
• 10/13/2025 – Nuvation Bio had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.

Insider Buying and Selling

In other news, insider Dongfang Liu sold 150,000 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $7.82, for a total transaction of $1,173,000.00. Following the completion of the sale, the insider directly owned 18,000 shares in the company, valued at approximately $140,760. This represents a 89.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Gary Hattersley sold 100,000 shares of the stock in a transaction on Monday, October 27th. The stock was sold at an average price of $5.02, for a total value of $502,000.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 320,000 shares of company stock valued at $2,050,800. 29.93% of the stock is owned by company insiders.

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.